{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:05:01Z","timestamp":1791669901375,"version":"4.3.4"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2025-0329_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Testosterone therapy is recommended for management of puberty from the age of 12\u00a0years in boys with Duchenne muscular dystrophy (DMD). Height measurement is problematic in these adolescent boys as lower limb contracture can be common and estimated height from segmental body part measurements may over-estimate height.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0329_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bone growth was assessed using metacarpal and phalangeal measurements from hand radiographs. Raw length measurements were converted to Z-scores based on published normative data and compared by calculating the mean of each patient as \u2018composite bone length Z-score\u2019. Biochemical data was also collected to monitor the safety of testosterone therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0329_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 22 boys with DMD on daily glucocorticoid were included in the study. Mean age at commencement of testosterone therapy was 14.05 (SD 1.20). 13 boys were commenced on intramuscular testosterone therapy and nine were commenced on topical testosterone therapy. At baseline, 20\/22 (91\u202f%) were pre-pubertal (G1). At follow-up, 16\/22 (77.3\u202f%) were at early stages of puberty (G2 or G3) and 6\/22 (22.7\u202f%) were at late stages of puberty (G4 or G5). At baseline and follow up, composite bone length Z-scores for chronological age were significantly lower than zero,\u00a0\u22122.7 (SD 1.07) (p&lt;0.001 vs. zero) and\u00a0\u22123.3 (SD 1.17), (p&lt;0.001 vs. zero), respectively. There were no statistically significant differences between the topical and IM group at baseline (p=0.61) or 1\u00a0year (p=0.40).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0329_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Measurements of metacarpophalangeal bone length confirms that testosterone therapy enhanced long bone growth in boys with DMD but does not achieve full catch-up growth. Both IM and topical testosterone effectively promote secondary sexual characteristics with no significant side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2025-0329","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T20:37:24Z","timestamp":1758227844000},"page":"1022-1032","source":"Crossref","is-referenced-by-count":1,"title":["Testosterone in Duchenne muscular dystrophy: effects on puberty and growth"],"prefix":"10.1515","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4607-789X","authenticated-orcid":false,"given":"Cara","family":"McCauley","sequence":"first","affiliation":[{"name":"School of Medicine , 3526 University of Glasgow , Glasgow , UK"},{"name":"Bone, Endocrine, Nutrition Research Group in Glasgow (BEN-G) Human Nutrition , University of Glasgow , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Smillie","sequence":"additional","affiliation":[{"name":"School of Medicine , 3526 University of Glasgow , Glasgow , UK"},{"name":"Bone, Endocrine, Nutrition Research Group in Glasgow (BEN-G) Human Nutrition , University of Glasgow , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dunne","sequence":"additional","affiliation":[{"name":"Department of Paediatric Neurology , Royal Hospital for Children , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Horrocks","sequence":"additional","affiliation":[{"name":"Department of Paediatric Neurology , Royal Hospital for Children , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuko","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Paediatric Neurology , Royal Hospital for Children , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"McNeilly","sequence":"additional","affiliation":[{"name":"Department of Biochemistry , Queen Elizabeth University Hospital , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2845-6555","authenticated-orcid":false,"given":"Sze Choong","family":"Wong","sequence":"additional","affiliation":[{"name":"School of Medicine , 3526 University of Glasgow , Glasgow , UK"},{"name":"Department of Paediatric Endocrinology , Royal Hospital for Children , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"2025111210012228755_j_jpem-2025-0329_ref_001","doi-asserted-by":"crossref","unstructured":"Birnkrant, DJ, Bushby, K, Bann, CM, Apkon, SD, Blackwell, A, Brumbaugh, D, et al.. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018;17:251\u201367. https:\/\/doi.org\/10.1016\/s1474-4422(18)30024-3.","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_002","doi-asserted-by":"crossref","unstructured":"Duan, D, Goemans, N, Takeda, S, Mercuri, E, Aartsma-Rus, A. Duchenne muscular dystrophy. Nat Rev Dis Primers 2021;7:13. https:\/\/doi.org\/10.1038\/s41572-021-00248-3.","DOI":"10.1038\/s41572-021-00248-3"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_003","doi-asserted-by":"crossref","unstructured":"Broomfield, J, Hill, M, Guglieri, M, Crowther, M, Abrams, K. Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis. Neurology 2021;97:e2304\u201314. https:\/\/doi.org\/10.1212\/wnl.0000000000012910.","DOI":"10.1212\/WNL.0000000000012910"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_004","doi-asserted-by":"crossref","unstructured":"McDonald, CM, Henricson, EK, Abresch, RT, Duong, T, Joyce, NC, Hu, F, et al.. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 2018;391:451\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(17)32160-8.","DOI":"10.1016\/S0140-6736(17)32160-8"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_005","doi-asserted-by":"crossref","unstructured":"Bello, L, Morgenroth, LP, Gordish-Dressman, H, Hoffman, EP, McDonald, CM, Cirak, S, et al.. DMD genotypes and loss of ambulation in the CINRG duchenne natural history study. Neurology 2016;87:401\u20139. https:\/\/doi.org\/10.1212\/wnl.0000000000002891.","DOI":"10.1212\/WNL.0000000000002891"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_006","doi-asserted-by":"crossref","unstructured":"Yilmaz, O, Karaduman, A, Topaloglu, H. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Eur J Neurol 2004;11:541\u20134. https:\/\/doi.org\/10.1111\/j.1468-1331.2004.00866.x.","DOI":"10.1111\/j.1468-1331.2004.00866.x"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_007","doi-asserted-by":"crossref","unstructured":"Matthews, E, Brassington, R, Kuntzer, T, Jichi, F, Manzur, AY. Corticosteroids for the treatment of Duchenne muscular dystrophy cochrane neuromuscular group, editor. Cochrane Database Syst Rev 2016. https:\/\/doi.org\/10.1002\/14651858.cd003725.pub4.","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_008","doi-asserted-by":"crossref","unstructured":"Biggar, WD, Harris, VA, Eliasoph, L, Alman, B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249\u201355. https:\/\/doi.org\/10.1016\/j.nmd.2006.01.010.","DOI":"10.1016\/j.nmd.2006.01.010"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_009","doi-asserted-by":"crossref","unstructured":"Lamb, MM, West, NA, Ouyang, L, Yang, M, Weitzenkamp, D, James, K, et al.. Corticosteroid treatment and growth patterns in ambulatory males with Duchenne muscular dystrophy. J\u00a0Pediatr 2016;173:207\u201313.e3. https:\/\/doi.org\/10.1016\/j.jpeds.2016.02.067.","DOI":"10.1016\/j.jpeds.2016.02.067"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_010","doi-asserted-by":"crossref","unstructured":"Wood, C, Page, J, Foggin, J, Guglieri, M, Straub, V, Cheetham, T. The impact of testosterone therapy on quality of life in adolescents with Duchenne muscular dystrophy. Neuromuscul Disord 2021;31:1259\u201365. https:\/\/doi.org\/10.1016\/j.nmd.2021.09.007.","DOI":"10.1016\/j.nmd.2021.09.007"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_011","doi-asserted-by":"crossref","unstructured":"West, NA, Yang, ML, Weitzenkamp, DA, Andrews, J, Meaney, FJ, Oleszek, J, et al.. Patterns of growth in ambulatory males with Duchenne muscular dystrophy. J\u00a0Pediatr 2013;163:1759\u201363.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2013.08.004.","DOI":"10.1016\/j.jpeds.2013.08.004"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_012","doi-asserted-by":"crossref","unstructured":"Sarrazin, E, Hagen, Mvon der, Schara, U, von Au, K, Kaindl, AM. Growth and psychomotor development of patients with Duchenne muscular dystrophy. Eur J Paediatr Neurol 2014;18:38\u201344. https:\/\/doi.org\/10.1016\/j.ejpn.2013.08.008.","DOI":"10.1016\/j.ejpn.2013.08.008"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_013","doi-asserted-by":"crossref","unstructured":"Wood, C, Cheetham, T, Guglieri, M, Bushby, K, Owen, C, Johnstone, H, et al.. Testosterone treatment of pubertal delay in Duchenne muscular dystrophy. Neuropediatrics 2015;46:371\u20136. https:\/\/doi.org\/10.1055\/s-0035-1563696.","DOI":"10.1055\/s-0035-1563696"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_014","doi-asserted-by":"crossref","unstructured":"Lee, SL-K, Lim, A, Munns, C, Simm, PJ, Zacharin, M. Effect of testosterone treatment for delayed puberty in Duchenne muscular dystrophy. Horm Res Paediatr 2020;93:108\u201318. https:\/\/doi.org\/10.1159\/000508290.","DOI":"10.1159\/000508290"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_015","doi-asserted-by":"crossref","unstructured":"Wood, CL, Hollingsworth, KG, Hughes, E, Punniyakodi, S, Muni-Lofra, R, Mayhew, A, et al.. Pubertal induction in adolescents with DMD is associated with high satisfaction, gonadotropin release and increased muscle contractile surface area. Eur J Endocrinol 2021;184:67\u201379. https:\/\/doi.org\/10.1530\/eje-20-0709.","DOI":"10.1530\/EJE-20-0709"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_016","doi-asserted-by":"crossref","unstructured":"Wood, CL, Hollingsworth, KG, Bokaie, E, Hughes, E, Muni-Lofra, R, Mayhew, A, et al.. Is ongoing testosterone required after pubertal induction in Duchenne muscular dystrophy? Endocr Connect 2023;12:e230245. https:\/\/doi.org\/10.1530\/ec-23-0245.","DOI":"10.1530\/EC-23-0245"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_017","doi-asserted-by":"crossref","unstructured":"Sodero, G, Cipolla, C, Rigante, D, Arzilli, F, Mercuri, EM. Pubertal induction therapy in pediatric patients with Duchenne muscular dystrophy. J\u00a0Pediatr Endocrinol Metab 2025. Available from https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2025-0061\/html","DOI":"10.1515\/jpem-2025-0061"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_018","doi-asserted-by":"crossref","unstructured":"Wang, B, Zhou, L, Li, S, Xu, H, Guo, Y, Hu, Q, et al.. Height development and multiple bone health indicators in children aged 2\u201312\u00a0years with duchenne muscular dystrophy (DMD). In: Brogna, C, editor; PLOS ONE. 2025, vol 20; e0316938. https:\/\/doi.org\/10.1371\/journal.pone.0316938.","DOI":"10.1371\/journal.pone.0316938"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_019","doi-asserted-by":"crossref","unstructured":"Garn, SM, Hertzog, KP, Poznanski, AK, Nagy, JM. Metacarpophalangeal length in the evaluation of skeletal malformation. Radiology 1972;105:375\u201381. https:\/\/doi.org\/10.1148\/105.2.375.","DOI":"10.1148\/105.2.375"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_020","doi-asserted-by":"crossref","unstructured":"Birnkrant, DJ, Bushby, K, Bann, CM, Alman, BA, Apkon, SD, Blackwell, A, et al.. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 2018;17:347\u201361. https:\/\/doi.org\/10.1016\/s1474-4422(18)30025-5.","DOI":"10.1016\/S1474-4422(18)30025-5"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_021","doi-asserted-by":"crossref","unstructured":"Salvi, R, Castillo, E, Voirol, M-J, Glauser, M, Rey, J-P, Gaillard, RC, et al.. Gonadotropin-releasing hormone-expressing neurons immortalized conditionally are activated by insulin: implication of the mitogen-activated protein kinase pathway. Endocrinology 2006;147:816\u201326. https:\/\/doi.org\/10.1210\/en.2005-0728.","DOI":"10.1210\/en.2005-0728"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_022","doi-asserted-by":"crossref","unstructured":"Salari, N, Fatahi, B, Valipour, E, Kazeminia, M, Fatahian, R, Kiaei, A, et al.. Global prevalence of duchenne and becker muscular dystrophy: a systematic review and meta-analysis. J\u00a0Orthop Surg 2022;17:96. https:\/\/doi.org\/10.1186\/s13018-022-02996-8.","DOI":"10.1186\/s13018-022-02996-8"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_023","doi-asserted-by":"crossref","unstructured":"Poznanski, AK, Garn, SM, Nagy, JM, Gall, JC. Metacarpophalangeal pattern profiles in the evaluation of skeletal malformations. Radiology 1972;104:1\u201311. https:\/\/doi.org\/10.1148\/104.1.1.","DOI":"10.1148\/104.1.1"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_024","unstructured":"Authority, HR. HRA decision tool: defining research; 2022. Available from https:\/\/www.hra-decisiontools.org.uk\/research\/docs\/DefiningResearchTable_Oct2022.pdf."},{"key":"2025111210012228755_j_jpem-2025-0329_ref_025","doi-asserted-by":"crossref","unstructured":"McCarrison, S, Denker, M, Dunne, J, Horrocks, I, McNeilly, J, Joseph, S, et al.. Frequency of delayed puberty in boys with contemporary management of Duchenne muscular dystrophy. J\u00a0Clin Res Pediatr Endocrinol 2024. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2024.2024-2-18. Available from https:\/\/jcrpe.org\/articles\/doi\/jcrpe.galenos.2024.2024-2-18.","DOI":"10.4274\/jcrpe.galenos.2024.2024-2-18"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_026","doi-asserted-by":"crossref","unstructured":"Giri, D, Patil, P, Blair, J, Dharmaraj, P, Ramakrishnan, R, Das, U, et al.. Testosterone therapy improves the first year height velocity in adolescent boys with constitutional delay of growth and puberty. Int J Endocrinol Metabol 2017. https:\/\/doi.org\/10.5812\/ijem.42311. Available from https:\/\/brieflands.com\/articles\/ijem-14627.html.","DOI":"10.5812\/ijem.42311"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_027","doi-asserted-by":"crossref","unstructured":"Mason, A, Wong, SC, McGrogan, P, Ahmed, SF. Effect of testosterone therapy for delayed growth and puberty in boys with inflammatory bowel disease. Horm Res Paediatr 2011;75:8\u201313. https:\/\/doi.org\/10.1159\/000315902.","DOI":"10.1159\/000315902"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_028","doi-asserted-by":"crossref","unstructured":"Dang, UJ, Damsker, JM, Guglieri, M, Clemens, PR, Perlman, SJ, Smith, EC, et al.. Efficacy and safety of vamorolone over 48\u00a0weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial. Neurology 2024;102:e208112. https:\/\/doi.org\/10.1212\/wnl.0000000000208112.","DOI":"10.1212\/WNL.0000000000208112"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_029","doi-asserted-by":"crossref","unstructured":"Hackett, G, Kirby, M, Rees, RW, Jones, TH, Muneer, A, Livingston, M, et al.. The British society for sexual medicine guidelines on Male adult testosterone deficiency, with statements for practice. World J Mens Health 2023;41:508. https:\/\/doi.org\/10.5534\/wjmh.221027.","DOI":"10.5534\/wjmh.221027"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_030","doi-asserted-by":"crossref","unstructured":"Stancampiano, MR, Lucas-Herald, AK, Russo, G, Rogol, AD, Ahmed, SF. Testosterone therapy in adolescent boys: the need for a structured approach. Horm Res Paediatr 2019;92:215\u201328. https:\/\/doi.org\/10.1159\/000504670.","DOI":"10.1159\/000504670"},{"key":"2025111210012228755_j_jpem-2025-0329_ref_031","doi-asserted-by":"crossref","unstructured":"McMillan, HJ, Gregas, M, Darras, BT, Kang, PB. Serum transaminase levels in boys with duchenne and becker muscular dystrophy. Pediatrics 2011;127:e132\u20136. https:\/\/doi.org\/10.1542\/peds.2010-0929.","DOI":"10.1542\/peds.2010-0929"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0329\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0329\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T10:01:33Z","timestamp":1762941693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0329\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,13]]},"published-print":{"date-parts":[[2025,10,27]]}},"alternative-id":["10.1515\/jpem-2025-0329"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2025-0329","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}